# Evaluation of the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Participants With Multiple Sclerosis

> **NCT04984278** · PHASE3 · TERMINATED · sponsor: **Jazz Pharmaceuticals** · enrollment: 56 (actual)

## Conditions studied

- Spasticity With Multiple Sclerosis

## Interventions

- **DRUG:** Nabiximols
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04984278
- **Lead sponsor:** Jazz Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-08-16
- **Primary completion:** 2022-11-11
- **Final completion:** 2022-11-11
- **Target enrollment:** 56 (ACTUAL)
- **Why stopped:** The study was terminated based on a business decision by the Sponsor.
- **Last updated:** 2024-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04984278

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04984278, "Evaluation of the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Participants With Multiple Sclerosis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04984278. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*